Abstract

BackgroundWe have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of iNOS regulating the activity of matrix metalloproteinases (MMPs). Here, the effects of OCA on MMP-2 and MMP-9 activity in liver, bile and serum were evaluated after hepatic ischemia/reperfusion (I/R) injury.Material and methodsMale Wistar rats (n = 20) were orally administered 10 mg/kg/day of OCA (5 days) and subjected to a 60-min ischemia and 60-min reperfusion. Bile, serum and tissue were collected for MMP-2 and MMP-9 activity quantification. The MMP regulator tissue reversion-inducing cysteine rich protein with Kazal motifs (RECK), tissue inhibitor of metalloproteinases (TIMPs), iNOS and biliary levels of LDH, γGT, glucose and ADMA were quantified.ResultsIn the I/R group, OCA administration reduced MMP-2 and MMP-9 in liver, bile and serum. A downregulation of tissue RECK and TIMPs, observed under I/R, were recovered by OCA. Immunohistochemical staining of hepatic tissue demonstrated that RECK expression is mainly localized in both cholangiocytes and hepatocytes. Hepatic iNOS positively correlated with tissue MMP-2 and MMP-9 activity. Biliary levels of LDH, γGT and glucose were lower in I/R rats treated with OCA; in bile, MMP levels positively correlated with LDH and γGT.ConclusionThus, OCA administration confers protection to cholangiocytes via downregulation of biliary MMPs in livers submitted to I/R. This event is associated with hepatic RECK- and TIMP-mediated MMP decrease.

Highlights

  • Obeticholic acid (OCA), a bile acid derivative and potent farnesoid X receptor (FXR) agonist, has been approved in the US and Europe for the treatment of primary biliary cholangitis (PBC) [1,2,3]

  • We have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of inducible nitric oxide synthase (iNOS) regulating the activity of matrix metalloproteinases (MMPs)

  • Biliary levels of lactate dehydrogenases (LDH), γGT and glucose were lower in I/R rats treated with OCA; in bile, MMP levels positively correlated with LDH and γGT

Read more

Summary

Introduction

Obeticholic acid (OCA), a bile acid derivative and potent farnesoid X receptor (FXR) agonist, has been approved in the US and Europe for the treatment of primary biliary cholangitis (PBC) [1,2,3]. In a model of rat ischemia/reperfusion (I/R) injury, the ability of OCA to upregulate the biliary excretion of asymmetric dimethylarginine (ADMA), a potent inhibitor of constitutive and inducible nitric oxide synthase (NOS) [6]. We demonstrated OCA’s ability to decrease iNOS content. This enzyme is involved in the pathogenesis of hepatic I/R injury as it synthesizes NO causing hemodynamic instability [7, 8]. We have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of iNOS regulating the activity of matrix metalloproteinases (MMPs). The effects of OCA on MMP-2 and MMP-9 activity in liver, bile and serum were evaluated after hepatic ischemia/reperfusion (I/R) injury.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call